The value of disease-free survival (DFS) and osimertinib in adjuvant non-small-cell lung cancer (NSCLC): an international Delphi consensus report
Authors:
Open Access
- 13 September 2022
- Vol. 7 (5) , 100572
Abstract
No abstract availableKeywords
This publication has 30 references indexed in Scilit:
- Adjuvant Erlotinib Versus Placebo in Patients With Stage IB-IIIA Non–Small-Cell Lung Cancer (RADIANT): A Randomized, Double-Blind, Phase III TrialJournal of Clinical Oncology, 2015
- Adjuvant cisplatin-based chemotherapy in nonsmall-cell lung cancer: new insights into the effect on failure type via a multistate approachAnnals of Oncology, 2014
- Disease-Free Survival as a Surrogate for Overall Survival in Adjuvant Trials of Gastric Cancer: A Meta-AnalysisJNCI: Journal of the National Cancer Institute, 2013
- Using the Delphi Technique to Improve Clinical Outcomes Through the Development of Quality Indicators in Renal Cell CarcinomaJournal of Oncology Practice, 2013
- Surrogate endpoints for overall survival in chemotherapy and radiotherapy trials in operable and locally advanced lung cancer: a re-analysis of meta-analyses of individual patients' dataThe Lancet Oncology, 2013
- EGFR mutation testing in lung cancer: a review of available methods and their use for analysis of tumour tissue and cytology samplesJournal of Clinical Pathology, 2012
- Review: Adjuvant therapy for resected non-small cell lung cancerTherapeutic Advances in Medical Oncology, 2009
- Lung Adjuvant Cisplatin Evaluation: A Pooled Analysis by the LACE Collaborative GroupJournal of Clinical Oncology, 2008
- Individual- and trial-level surrogacy in colorectal cancerStatistical Methods in Medical Research, 2008
- Meta-Analysis of Randomized Clinical Trials Comparing Cisplatin to Carboplatin in Patients With Advanced Non–Small-Cell Lung CancerJournal of Clinical Oncology, 2004